Sourav Bandyopadhyay, Ph.D.
Affiliations: | Bioinformatics | University of California, San Diego, La Jolla, CA |
Area:
computational biologyGoogle:
"Sourav Bandyopadhyay"Parents
Sign in to add mentor| Trey Ideker | grad student | 2010 | UCSD | |
| (Integrating physical and genetic interaction networks for biological pathway discovery.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Pucciarelli D, Angus SP, Huang B, et al. (2020) Nf1 mutant tumors undergo transcriptome and kinome re-modeling after inhibition of either mTOR or MEK. Molecular Cancer Therapeutics |
| Maynard A, McCoach CE, Rotow JK, et al. (2020) Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing. Cell |
| Wu CH, Yang CY, Wang L, et al. (2020) Cutaneous T cell lymphoma PDX drug screening platform identifies cooperation between inhibitions of PI3Kα/δ and HDAC. The Journal of Investigative Dermatology |
| Ku AA, Hu HM, Zhao X, et al. (2020) Integration of multiple biological contexts reveals principles of synthetic lethality that affect reproducibility. Nature Communications. 11: 2375 |
| Shah KN, Bhatt R, Rotow J, et al. (2019) Abstract 2902: Non-genetic TPX2/AURKA signaling facilitates tumor evolution in EGFR-TKI resistance in NSCLC Cancer Research. 79: 2902-2902 |
| Webber JT, Kaushik S, Bandyopadhyay S. (2018) Integration of Tumor Genomic Data with Cell Lines Using Multi-dimensional Network Modules Improves Cancer Pharmacogenomics. Cell Systems |
| Donnella HJ, Webber JT, Levin RS, et al. (2018) Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology |
| Hu HM, Zhao X, Kaushik S, et al. (2018) A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance. Cell Reports. 23: 918-929 |
| Martinko AJ, Truillet C, Julien O, et al. (2018) Targeting RAS driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. Elife. 7 |
| Donnella H, Webber J, Shokat K, et al. (2018) Abstract A45: Kinome rewiring reveals AURKA is a molecular barrier to the efficacy of PI3K/mTOR-pathway inhibitors in breast cancer Molecular Cancer Research. 16 |